Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04512963 · ClinicalTrials.gov registry record · Phase 1
Phase I Study of Progerinin in Healthy Volunteers
A Phase 1 study of Hutchinson-Gilford Progeria Syndrome and Werner Syndrome, sponsored by PRG Science & Technology Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT04512963 is a Phase 1 study of Hutchinson-Gilford Progeria Syndrome and Werner Syndrome that has completed, run by PRG Science & Technology Co.. The registered enrollment target is 64 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04512963, a Phase 1 study of Hutchinson-Gilford Progeria Syndrome and Werner Syndrome, has completed, sponsored by PRG Science & Technology Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
PRG-PRO-001 is a Phase I, Randomized, Double-blind, Placebo-Controlled, Single Ascending Dose (SAD) Study including a food interaction study, followed by a Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Profile of Progerinin in Healthy Volunteers. This is a first-in-human study. The study aims to determine the safety and tolerability of Progerinin after single and multiple doses in healthy volunteers and to evaluate the pharmacokinetics (PK) of Progerinin after single and multiple dose administrations in healthy volunteers.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Progerinin
Study Locations (1)
California
- PRG S&T Investigational Site - Glendale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2020-08-24 |
| Est. Completion | 2021-07-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04512963
The ClinicalTrials.gov registry entry for NCT04512963 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PRG Science & Technology Co., which has 3 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Hutchinson-Gilford Progeria Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04512963 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04512963 about?
NCT04512963 is a clinical study titled "Phase I Study of Progerinin in Healthy Volunteers". PRG-PRO-001 is a Phase I, Randomized, Double-blind, Placebo-Controlled, Single Ascending Dose (SAD) Study including a food interaction study, followed by a Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Profile of Progerinin in Healthy ...
What is the current status of trial NCT04512963?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 64 participants. The study started on 2020-08-24. Estimated completion is 2021-07-27.
What conditions does trial NCT04512963 study?
This clinical trial studies the following conditions: Hutchinson-Gilford Progeria Syndrome, Werner Syndrome.
What interventions are being tested in trial NCT04512963?
The interventions under investigation include: Placebo (DRUG), Progerinin (DRUG).
Who is sponsoring clinical trial NCT04512963?
This trial is sponsored by PRG Science & Technology Co., which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04512963 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hutchinson-Gilford Progeria Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.